Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
NCT06492408
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Hepatic Cancer
Surgery
Interventions
DRUG:
ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Sponsor
Second Affiliated Hospital of Guangzhou Medical University